Loading…
Employees: 574
Size Zhejiang Laifual Drive (3952.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $363M, the 839th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$27.34 on 6 Nov 2026.
Growth Revenue grew 142.2% over the last twelve months (peer median -4.1%); the operating margin is -11.4% (peer median -856.9%).
Valuation It trades at 7.1× enterprise value to sales against a peer median of 22.8× (7th cheapest of 16).
Capital Return on invested capital runs 10.0 points below its cost of capital (6.0% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | HK$283M | HK$117M | HK$104M |
| Revenue growth | — | +142% | +12% | — |
| Gross profit | n/a | HK$63.2M | HK$21.1M | HK$22.9M |
| EBITDA | n/a | -HK$4.90M | -HK$9.05M | -HK$8.49M |
| Net income | n/a | -HK$185M | -HK$183M | -HK$187M |
| Free cash flow | n/a | -HK$201M | -HK$80.6M | -HK$107M |
| Capital expenditure | n/a | HK$128M | HK$52.2M | HK$68.6M |
| Total debt | n/a | HK$1.60B | HK$1.19B | HK$1.04B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3952.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -36.6% | -7.7% | lowest of 20 |
| Distance from 52-week high | -77.1% | -51.2% | 2nd lowest of 20 |
| Revenue growth (TTM) | +142.2% | -4.1% | 2nd highest of 16 |
| Operating margin | -11.4% | -856.9% | 6th highest of 16 |
| EV / Sales | 7.1× | 22.8× | 7th cheapest of 16 |
| ROIC minus cost of capital | -10.0 pp | -66.5 pp | 5th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |